| __timestamp | Dynavax Technologies Corporation | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84580000 | 79696000 |
| Thursday, January 1, 2015 | 86943000 | 93236000 |
| Friday, January 1, 2016 | 84493000 | 150842000 |
| Sunday, January 1, 2017 | 64988000 | 150643000 |
| Monday, January 1, 2018 | 74951000 | 150252000 |
| Tuesday, January 1, 2019 | 62331000 | 140804000 |
| Wednesday, January 1, 2020 | 28607000 | 34236000 |
| Friday, January 1, 2021 | 32228000 | 35672000 |
| Saturday, January 1, 2022 | 46600000 | 66607000 |
| Sunday, January 1, 2023 | 54886000 | 76363000 |
In pursuit of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. and Dynavax Technologies Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Halozyme consistently allocated a higher percentage of its budget to R&D, peaking in 2016 with a 90% increase compared to 2014. In contrast, Dynavax's R&D spending saw a significant dip in 2020, dropping by nearly 66% from its 2015 peak. However, both companies have shown resilience, with a gradual recovery in their R&D investments by 2023. This trend underscores the dynamic nature of the biotech industry, where strategic R&D allocation can be the key to unlocking groundbreaking therapies and maintaining a competitive edge.
Eli Lilly and Company or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Merck & Co., Inc. vs Dynavax Technologies Corporation
Pfizer Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
BeiGene, Ltd. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Research and Development Investment: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Research and Development Investment: BioMarin Pharmaceutical Inc. vs Dynavax Technologies Corporation
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.